Kevetrin hydrochloride


Catalog No. Size 价格库存数量
S0272-2 2mg solid ¥90
S0272-10 10mg solid ¥270


Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Target:p53 in vitro: Kevetrin activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Kevetrin may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells. in vivo: Kevetrin has demonstrated potent anti-tumor efficacy against various carcinoma xenograft models: lung, breast, colon, prostate and squamous cell carcinoma, and in a leukemia tumor model. In drug-resistant cell lines, Kevetrin has shown excellent activity, galvanizing the Company to focus on Kevetrin's development potential in this area.

Product information

CAS Number: 66592-89-0

Molecular Weight: 179.67

Formula: C5H10ClN3S


4-Isothioureidobutyronitrile hydrochloride

thioureidobutyronitrile hydrochloride

thioureido butyronitrile hydrochloride

Chemical Name: 4-(carbamimidoylsulfanyl)butanenitrile hydrochloride

Smiles: Cl.NC(=N)SCCCC#N


InChi: InChI=1S/C5H9N3S.ClH/c6-3-1-2-4-9-5(7)8;/h1-2,4H2,(H3,7,8);1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 40 mg/mL (222.63 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200


  1. Han D., Smalley K. (2015) Targeting the Cell Cycle and p53 in Combination with?BRAF-Directed Therapy. In: Sullivan R. (eds) BRAF Targets in Melanoma. Cancer Drug Discovery and Development, vol 82. Springer, New York, NY

Products are for research use only. Not for human use.


Recently viewed